Ocimene

Ocimene

SCHEMBL83330

C=C/C(C)=C\CC=C(C)C

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
ALDH1A1 P00352 2/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ocimene SCHEMBL157852 1.00 TSHR (0.41) TSHRALDH1A1TP53ALOX15
Ocimene SCHEMBL23589 1.00 TSHR (0.41) TSHRALDH1A1TP53ALOX15
Ocimene SCHEMBL15011309 1.00 TSHR (0.41) TSHRALDH1A1TP53ALOX15
Ocimene SCHEMBL15011308 0.83 TSHR (0.48) TSHRALDH1A1ALOX15
Ocimene SCHEMBL30518211 0.82 TSHR (0.32) TSHR
Ocimene SCHEMBL29414419 0.82 TSHR (0.32) TSHR
Ocimene SCHEMBL16011222 0.82 BTN3A1 (0.46)
Ocimene SCHEMBL8201861 0.82 NR1I2 (0.37) TSHR
SCHEMBL8070910 0.81 ALDH1A1 (0.32) TSHRALDH1A1TP53
SCHEMBL25416695 0.80 KMT2A (0.56) TSHRALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 930 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3868206-B1 A METHOD FOR THE HERBICIDAL TREATMENT OF DICOTYLEDONOUS WEEDS RENDAPART (BE) 2026-05-20 EP claimed
US-20260124219-A1 CANNABINOID COMPOSITIONS AND METHODS OF USE THEREOF FOR IMMUNE MODULATION SRIN THERAPEUTICS INC (US) 2026-05-07 US claimed
EP-4709355-A1 CANNABINOID-BASED FORMULATION MRX Medical Limited (GB) 2026-03-18 EP claimed
EP-4687452-A1 ESSENTIAL OIL IMPREGNATED DEVICE AND METHODS OF USE THEREOF Pertinent Eco-Solutions Inc. (US) 2026-02-11 EP claimed
EP-4680720-A1 OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS EvodiaBio ApS (DK) 2026-01-21 EP claimed
US-12529077-B2 Production of geranyl diphosphate-derived compounds Københavns Universitet (DK) 2026-01-20 US claimed
US-12495802-B2 Phagostimulant formulation for control of pest R, Manoj Kumar (IN) 2025-12-16 US claimed
US-12439914-B2 Bactrocera oleae attractant composition and uses thereof CEARITIS (FR) 2025-10-14 US claimed
US-20250304517-A1 STERIOISOMER-SPECIFIC CANNABIS FORMULATIONS AND ANALYSIS SCIENTIFIC HOLDINGS, LLC (US) 2025-10-02 US claimed
US-20250205127-A1 COSMETIC AND NON-COSMETIC COMPOSITIONS AND METHODS OF USE K&K BIOTECH (US) 2025-06-26 US claimed
WO-2010148144-A1 POLYMERIZATION OF ISOPRENE FROM RENEWABLE RESOURCES DANISCO US INC. (US) 2010-12-23 WO claimed
US-20100048964-A1 COMPOSITIONS AND METHODS FOR PRODUCING ISOPRENE FREE OF C5 HYDROCARBONS UNDER DECOUPLING CONDITIONS AND/OR SAFE OPERATING RANGES DANISCO US INC. 2010-02-25 US claimed
WO-2010003007-A2 COMPOSITIONS AND METHODS FOR PRODUCING ISOPRENE FREE OF C5 HYDROCARBONS UNDER DECOUPLING CONDITIONS AND/OR SAFE OPERATING RANGES DANISCO US INC. (US) 2010-01-07 WO claimed
US-20070264363-A1 Molluscicidal and Anti-Barnacle Compounds COMPTON DEVEOLOPMENT LTD (GB) 2007-11-15 US claimed
EP-1682107-A1 ANTI-TUMOUR TERPENE COMPOUNDS Compton Developments, Ltd. (GB) 2006-07-26 EP claimed
EP-1681933-A2 MOLLUSCICIDAL AND ANTI-BARNACLE COMPOUNDS Compton Developments, Ltd. (GB) 2006-07-26 EP claimed
WO-2005051083-A2 MOLLUSCICIDAL AND ANTI-BARNACLE COMPOUNDS COMPTON DEVELOPMENTS LTD (GB) 2005-06-09 WO claimed
WO-2005049001-A1 ANTI-TUMOUR TERPENE COMPOUNDS COMPTON DEVELOPMENTS LTD (GB) 2005-06-02 WO claimed
US-20040247669-A1 Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth BENNES, INC. 2004-12-09 US claimed
US-20040151771-A1 Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth BENNES, INC. 2004-08-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12529077-B2 Production of geranyl diphosphate-derived compounds GGPS1, OGA, GBA3 TSHR 4055/4885ALDH1A1 2747/4885TP53 3171/4885
US-20070264363-A1 Molluscicidal and Anti-Barnacle Compounds ACHE, BROX, BAD TSHR 4817/4885ALDH1A1 525/4885TP53 4825/4885
US-20260124219-A1 CANNABINOID COMPOSITIONS AND METHODS OF USE THEREOF FOR IMMUNE MODULATION DEGS1, CNR2, CNR1 TSHR 4183/4885ALDH1A1 3407/4885TP53 3340/4885
US-20250205127-A1 COSMETIC AND NON-COSMETIC COMPOSITIONS AND METHODS OF USE KEAP1, NFE2, NFE2L2 TSHR 4234/4885ALDH1A1 422/4885TP53 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.